Laronidase

(Aldurazyme^®) Approved

A hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme used to treat mucopolysaccharidosis I (MPS I).

Research Code BM-101; JC-0498

CAS No. 210589-09-6

EZN-2279

Phase III Active

A polyethylene glycol recombinant adenosine deaminase (ADA) potentially for the treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency disease (SCID).

Research Code EZN-2279; STM-279; rhADA; PEG-rADA

CAS No. 9026-93-1 (Adenosine deaminase)

Lesinidase alfa

Phase II Active

A recombinant human NaGlu potentially for the treatment of mucopolysaccharidosis IIIB.

Research Code SBC-103; rhNaGlu; 61A4G0P3IB

CAS No. 1802497-18-2

Rasburicase biosimilar (Virchow Group)

(Tuly^®) Active

A recombinant urate oxidase potentially for the prevention and treatment of malignancy-associated hyperuricaemia.

Research Code

CAS No. 134774-45-1 (Rasburicase)

SHP-610

Phase II Active

A recombinant human heparan N-sulfatase potentially for the treatment of mucopolysaccharidosis IIIA (MPS IIIA/Sanfilippo syndrome type A).

Research Code SHP-610; HGT-1410

CAS No.

Pegloticase

(Krystexxa, Puricase^®) Approved

A PEGylated uric acid specific enzyme used to treat chronic gout.

Research Code

CAS No. 885051-90-1

Agalsidase beta

(Fabrazyme^®) Approved

A recombinant human α-galactosidase used to treat Fabry disease.

Research Code

CAS No. 104138-64-9

MEDI-6012

Phase II Active

A recombinant human lecithin-cholesterol acyltransferase (LCAT) potentially for the treatment of acute coronary syndrome (ACS) and coronary artery disease (CAD).

Research Code ACP-501; MEDI-6012; rhLCAT

CAS No.

Recombinant human prourokinase

(普佑克^®) Approved

A recombinant human prourokinase used to treat acute myocardial infarction.

Research Code

CAS No.

Recombinant staphylokinase (Shanghai Tonghuayujin)

(施爱克^®) Approved

A recombinant staphylokinase used to treat acute myocardial infarction.

Research Code

CAS No. 9040-61-3

Idursulfase

(Elaprase^®) Approved

A hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme used to treat Hunter syndrome (Mucopolysaccharidosis II, MPS II).

Research Code SHP-609; GC-1111; HGT-2310; I2S; EC-3.1.6.13

CAS No. 50936-59-9

Recombinant streptokinase (Qingdao Guoda)

( 国大欣通^®) Approved

A recombinant streptokinase used to treat acute myocardial infarction.

Research Code

CAS No. 9002-01-1

Recombinant human cathepsin L (Halozyme Therapeutics)

Phase II Active

A recombinant human cathepsin-L potentially for treatment of cellulite.

Research Code HTI-501; rHuCAT-L

CAS No.

Pegadricase

Phase II Active

A pegylated formulation of urate oxidase potentially for the treatment of gout and tumour lysis syndrome.

Research Code SEL 037; SSS-11; Uricase-PEG 20

CAS No. 1040753-26-1

Nateplase

(Milyzer, Tepase^®) Approved

A recombinant single-chain human tissue-type plasminogen activator used to treat myocardial infarction.

Research Code MMR-701

CAS No. 159445-63-3

Recombinant lipase (Mayoly-Spindler/AzurRx BioPharma)

Phase II Active

A yeast-derived recombinant lipase potentially for the treatment of pancreatitis.

Research Code MS-1819; MS-1819-SD 

CAS No.

Lecithin-modified superoxide dismutase

Phase II Active

A superoxide dismutase analogue potentailly for the treatment of interstitial lung diseases and ulcerative colitis.

Research Code LT-0011; PCSOD; PCSOD-NE

CAS No.

Cerliponase alfa

(Brineura^®) Approved

A recombinant human tripeptidyl peptidase-1 (rhTPP1) enzyme replacement therapy used to treat neuronal ceroid lipofuscinosis type 2 (CLN2/LINCL).

Research Code BMN-190

CAS No. 151662-36-1

Monteplase

(Cleactor^®) Approved

A recombinant tissue plasminogen activator used to treat acute myocardial infarction and acute massive pulmonary embolism.

Research Code E-6010; Mf-tPA

CAS No. 105913-11-9

GSK-2586881

Phase II Active

A recombinant angiotensin converting enzyme-2 (rhACE2) potentially for the treatment of acute lung injury and respiratory distress syndrome.

Research Code APN-01; GSK-2586881; rhACE2; 2586881

CAS No.